India Glycols demerger approved: key dates, ratios in 2026

What the NCLT order changes for India Glycols

India Glycols Limited has received the certified true copy of the National Company Law Tribunal (NCLT) order approving its composite demerger scheme. The order was sanctioned by the NCLT Allahabad Bench on July 17, 2026, and the company said it formally received the document on August 20, 2026. The approved arrangement splits India Glycols into three distinct entities after transferring two undertakings into two resulting companies. The move is structured as a scheme of arrangement under Sections 230 and 232 of the Companies Act, 2013.

The company has described the transaction as a composite scheme involving the demerger of its Bio Pharma undertaking into Ennature Bio Pharma Limited and its Spirits and Biofuel undertaking into IGL Spirits Limited. India Glycols continues as the demerged company, while the two resulting companies house the carved-out businesses. The appointed date has been set as April 1, 2026. However, the effective date and record date for the scheme will be decided by the boards of the companies involved and communicated later.

Timeline: from reservation of order to receipt of certified copy

The NCLT process shows multiple dated milestones. The Allahabad Bench at Prayagraj reserved the matter for final pronouncement on July 2, 2026. The order was uploaded on the NCLT website on July 3, 2026, as per the available details. The scheme was later sanctioned on July 17, 2026. India Glycols then reported receiving the certified true copy on August 20, 2026.

Separately, the company stated it achieved complete stakeholder consensus earlier in the year. Equity shareholders voted in favour with 4,42,48,625 votes, described as 100% support. Unsecured creditors also approved unanimously, with support valued at ₹64,266.50 lakh.

How the business will be split between the resulting companies

Under the approved scheme, the undertakings are divided between two resulting companies. Ennature Bio Pharma Limited receives the Biopharma undertaking. IGL Spirits Limited receives the Spirits and Biofuel undertaking. India Glycols remains the demerged company after these transfers, leading to three listed or operating entities post-restructuring (as described in the scheme summary).

The scheme also states that existing equity shares held by India Glycols in the resulting companies will be cancelled once the scheme becomes effective. This is an important technical point for capital structure after the reorganisation, because it addresses cross-holdings that can arise during such restructurings.

Share entitlement: what shareholders are set to receive

The scheme specifies share allotment ratios for shareholders of India Glycols. Shareholders are set to receive shares in both resulting companies, based on their holding in India Glycols as of the scheme’s record date (to be announced). The ratios disclosed are different for the two resulting companies, reflecting the structure of the split.

Key ratios disclosed in the scheme

The company has clarified that the effective date and record date will be decided by the boards of all involved companies and communicated subsequently. That means the entitlement date for investors is not yet fixed in the disclosed information, even though the appointed date is April 1, 2026.

Post-restructuring promoter holding

India Glycols has stated that, post-restructuring, promoters will hold 59.63% in each of the three resulting companies: India Glycols Limited, IGL Spirits Limited, and Ennature Biopharma Limited. This indicates the promoter group’s stated ownership level is planned to remain consistent across the entities created by the demerger, based on the scheme details provided.

The promoter percentage was also shown as 59.63% in the company information snapshot included in the provided data. Investors typically track this figure closely during demergers because the final shareholding pattern depends on the allotment mechanics and regulatory filings after effectiveness.

Dividend timeline and investor eligibility: March 2026 dates

Alongside the restructuring updates, the provided details include multiple references to India Glycols’ interim dividend for FY 2025-26. The company declared an interim dividend of ₹7.50 per equity share (150% rate), with board approval on March 17, 2026. The record date was fixed as March 23, 2026, and the ex-dividend date is also shown as March 23, 2026.

Eligibility was described in standard terms: registered shareholders who own the shares on or before the record date are eligible, while purchases on or after the ex-dividend date do not qualify. The company also indicated the interim dividend would be paid within 30 days from the date of declaration to eligible shareholders whose names appear in company records or depository records as beneficial owners.

Dividend related data points in the provided information

The provided dataset also includes additional dividend-related references such as a “latest dividend” of 1.5 per share for the financial year announced on March 23, 2026, and a statement that for 2025-26 the company declared a final dividend of 1.18% per share. Because these appear as separate lines without reconciliation, investors should rely on the company’s exchange filings for the definitive dividend classification and amount.

Other disclosed corporate and operational updates

The scheme has been processed under Sections 230 and 232 of the Companies Act, 2013. In another update tied to the restructuring ecosystem, IGL Spirits Limited, described as a wholly owned subsidiary of India Glycols Limited, appointed Manoj Kumar Rai as its Chief Operating Officer effective July 2, 2026.

The data also mentions India Glycols Limited received ₹32.40 crore net interim dividend from its joint venture Clariant IGL Specialty Chemical Private Limited on March 17, 2026. This is a separate cash flow reference from the dividend paid by India Glycols to its own shareholders.

Market snapshot points cited in the provided data

A company snapshot included in the provided information lists a market capitalisation of ₹7,187.95 (unit not specified in the text) and a PE of 24, while PB is shown as N/A. The stock is tagged under “Commodity Chemicals” in the snapshot line. These figures are presented as-is from the provided dataset and should be cross-checked with market data platforms for current values.

Why this demerger matters for investors tracking India Glycols

Demerger schemes typically change how investors view a group’s different business lines because each resulting company can be evaluated on its own business performance, strategy, and peer set. In this case, the scheme explicitly separates Biopharma from Spirits and Biofuel into two resulting companies, while India Glycols remains as the demerged entity. The disclosed share allotment ratios set expectations for the number of shares investors may receive in each resulting company, subject to the final record date and effectiveness.

From a process perspective, the sanction by the NCLT, receipt of the certified copy, and the earlier unanimity among shareholders and creditors together show the scheme has cleared key steps that are usually material for corporate restructuring timelines. The next practical milestones for investors will be the boards’ announcement of the effective date and the record date for share entitlement, followed by filings and listing-related steps, if applicable.

Conclusion

India Glycols’ composite demerger has been sanctioned by the NCLT Allahabad Bench, with an appointed date of April 1, 2026 and share entitlement ratios of 1:3 for Ennature Bio Pharma and 1:1 for IGL Spirits. The company received the certified true copy of the order on August 20, 2026, after the sanction dated July 17, 2026. The effective date and the scheme record date are still pending board decisions and further communication. Investors will likely watch for those announcements to understand the exact entitlement timeline and next operational steps for the three-entity structure.